Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products
Authors:
- 20 July 2009
- journal article
- review article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 44 (4) , 205-211
Abstract
The irradiation of cellular blood components to prevent transfusion-associated (TA)-GVHD is an established practice in the developed world. Susceptible patients include those who are immunosuppressed, fetuses, very premature neonates and patients who have an increased likelihood of possessing one HLA haplotype for which the blood component donor is homozygous. Problems and challenges associated with blood component irradiation include transfusion delay, cost, failure to irradiate when indicated, increased potassium accumulation in and decreased shelf life of RBC units, reduced RBC recovery and, in the United States, substantial and onerous security requirements for cesium-137 source irradiators and their operators. Microbial contamination of blood components can pose life-threatening risks for transfusion recipients. Donor history screening and infectious disease testing are a reactive response and expensive, as well as an imperfect and incomplete means for preventing these infectious risks. In response to these threats, pathogen reduction technologies have been developed. Two such innovations (INTERCEPT, Cerus Corporation, Concord, CA, USA; and Mirasol, CaridianBCT Biotechnologies, Lakewood, CO, USA) are approved for clinical use in many countries, though not in the United States. These processes have been shown to effectively prevent proliferation of nucleic acid-containing microbes, thereby providing broad protection against transfusion-transmitted infection. These technologies have also been shown to prevent the replication of WBC. In this report, we review the substantial in vitro, clinical trial and clinical practice observational evidence that non-irradiated INTERCEPT- and Mirasol-treated cellular blood components do not cause TA-GVHD. Implementation of these processes precludes the necessity for irradiating cellular blood components to prevent TA-GVHD.Keywords
This publication has 30 references indexed in Scilit:
- Impact of donor deferrals for malaria on blood availability in the United StatesTransfusion, 2008
- A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh‐frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpuraTransfusion, 2006
- Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver diseaseBlood, 2006
- Fresh frozen plasma prepared with amotosalen HCl (S‐59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficienciesTransfusion, 2005
- Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT TrialBlood, 2004
- Diagnosis of transfusion‐associated graft‐versus‐host disease by polymerase chain reaction in fludarabine‐treated B‐chronic lymphocytic leukaemiaBritish Journal of Haematology, 1995
- The Role of Blood from HLA-Homozygous Donors in Fatal Transfusion-Associated Graft-versus-Host Disease after Open-Heart SurgeryNew England Journal of Medicine, 1989
- Graft versus host disease after transfusions of non-irradiated blood cells in patients having received autologous bone marrowEuropean Journal of Cancer and Clinical Oncology, 1988
- Graft-Versus-Host Disease in Consecutive Patients with Acute Myeloid Leukaemia Treated with Blood Cells from Normal DonorsAustralian and New Zealand Journal of Medicine, 1981
- Acute leukemia and granulocyte transfusion: Fatal graft-versus-host reaction following transfusion of cells obtained from normal donorsThe Journal of Pediatrics, 1978